6H2单克隆抗体靶向脂肪酸结合蛋白减轻脂多糖诱导脓毒症的全身炎症和器官损伤OA
Targeting Fatty Acid-binding Protein with 6H2 Monoclonal Antibody Mitigates Systemic Inflammation and Organ Damage in LPS-induced Sepsis
炎症失调与多器官衰竭是脓毒症的典型特征,这种潜在致命性疾病目前尚无有效疗法.近期研究发现,脂肪酸结合蛋白(A-FABP)是脓毒症炎症通路的关键介质.本研究采用脂多糖诱导的小鼠浓度症模型,评估了靶向A-FABP的单克隆抗体 6H2的治疗潜力.与未经治疗的脓毒症小鼠相比,6H2治疗显著提高存活率,减轻肝脏、肺部、肾脏和心脏的组织病理损伤,并降低全身炎症反应.生化分析显示,6H2治疗能降低循环系统中A-FABP水平,这与炎症标志物的减少密切相关.这些结果表明,抑制A-FABP是治疗脓毒症的潜在有效策略,6H2展现出强大的治疗潜力.
Dysregulated inflammation and multi-organ failure are hallmarks of sepsis,a potentially fatal illness for which there are currently no effective treatments.Fatty acid-binding protein(A-FABP)has been identified in recent research as a crucial mediator of the inflammatory pathways underlying sepsis.In this study,we used a murine model of lipopolysaccharide(LPS)-induced endotoxemia to assess the therapeutic potential of 6H2,a monoclonal antibody that targets A-FABP.In comparison to untreated septic mice,6H2 treatment significantly increased survival rates,decreased histopathological damage in the liver,lungs,kidneys,and heart,and reduced systemic inflammation.According to biochemical analyses,6H2 treatment decreased circulating levels of A-FABP,and this was associated with a reduction in inflammatory markers.These results indicate that A-FABP inhibition is a potentially effective treatment approach for sepsis,with 6H2 demonstrating strong therapeutic efficacy.
Muhammad Mustapha IBRAHIM;方程
中国科学院深圳先进技术研究院 深圳 518055||中国科学院大学 北京 100049中国科学院深圳先进技术研究院 深圳 518055||中国科学院大学 北京 100049
生物科学
脓毒症脂肪酸结合蛋白脂多糖
sepsisfatty acid-binding proteinLPS
《集成技术》 2026 (1)
56-66,11
国家自然科学基金项目(31900704)广东省基础与应用基础研究基金项目(2023A1515010467)深圳市科技创新委员会项目(JCYJ20230807140721043) This work is supported by National Natural Science Foundation of China(31900704),Guangdong Basic and Applied Basic Research Foundation(2023A1515010467),Science Technology and Innovation Commission of Shenzhen Municipality(JCYJ20230807140721043)
评论